drugset / Trial / NCT07053176

Impact of Local Lidocaine Paravertebral Cervical Injection on Cervicogenic Dizziness Symptoms

NCT07053176 ↗

Phase 4 Enrolling by invitation 42 enrolled Uniter Onlus
RandomizedParallel-groupTriple-blindTreatment

Summary

at least 42 patients affected by cervicogenic dizziness will be allocated to the experimental group or in the placebo group. in the first group patients will received 2 paravertebral intramuscular injection of lidocaine 0.5% while in the placebo group they will received saline solution with the same injection technique. patients will be evaluated by subjective and objective testing before the treatment, immediatly and 3 months after the treatment.

Timeline

Start
2025-08-01
Primary completion
2025-09-15
Completion
2025-09-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 0.5 % Intramuscular

Indications